Machine Learning Model for Prediction of acute orthostatic hypotension after levodopa administration
Objective: The aim of this study is to develop and validate a prediction model of AOHPL to facilitate physicians in identifying patients at higher probability…Tremor characteristics differentially respond to levodopa and subthalamic nucleus deep brain stimulation in Parkinson’s disease
Objective: To identify factors predictive of responsiveness of tremor to levodopa and STN-DBS. Background: Tremor in Parkinson’s disease (PD) is phenotypically variable and has an…Levodopa-induced orthostatic hypotension in a large cohort of patients with Parkinson’s disease undergoing an acute levodopa challenge test
Objective: We aimed to investigate the frequency and associated risk factors for Levodopa-induced orthostatic hypotension (OH) in a large cohort of PD patients underwent acute…15-year effects of initiating treatment for Parkinson’s disease with dopamine agonists or monoamine oxidase B inhibitors compared with levodopa: final results of PD MED early disease randomisation
Objective: PD MED EARLY is a large, pragmatic trial aiming to determine which class of drug as initial treatment provides the most effective long-term control…Reductions in OFF time with ND0612 for patients with Parkinson’s disease experiencing motor fluctuations: Responder-analysis from an open-label Phase 2 study
Objective: Evaluate the efficacy of subcutaneous levodopa/carbidopa infusion with investigational ND0612 in reducing OFF time in people with Parkinson’s disease (PwP) experiencing motor fluctuations. Background:…Developement and acceptability testing of a patient decision aid on levodopa/carbidopa intestinal gel.
Objective: To develop a patient decision aid on levodopa/carbidopa intestinal gel (LCIG) and to test its acceptability. Background: : Advanced Parkinson’s disease (PD) is characterized…How to dose extended-release carbidopa-levodopa capsules (IPX203) in Parkinson’s disease patients: Experience from the Phase 3 clinical trial
Objective: To provide guidance on dosing of IPX203 based on clinical trial experience. Background: IPX203 is an extended-release, oral carbidopa-levodopa (CD-LD) formulation designed to rapidly…Initial 24-hours Levodopa Carbidopa Intestinal Gel initiation in advanced Parkinson’s disease
Objective: To evaluate the profile of those patients with advanced Parkinson’s Disease (APD) in which we decided to use continuous 24-hour administration of Levodopa Carbidopa…Improvement in motor symptoms and quality of life in patients with an earlier stage of advanced Parkinson’s disease treated with foslevodopa/foscarbidopa subcutaneous 24 hour infusion
Objective: To evaluate whether treatment with foslevodopa/foscarbidopa (LDP/CDP), a continuous (24‑hour/day) subcutaneous infusion of carbidopa/levodopa prodrugs, improves motor fluctuations and quality of life (QoL) in…A randomized, phase 2a, double-blind, placebo-controlled clinical trial with NE3107 adjunctive to carbidopa/levodopa in patients with Parkinson’s disease
Objective: To evaluate the motor effects of NE3107 treatment in patients with levodopa-treated Parkinson’s disease (PD) experiencing motor fluctuations. Background: NE3107 is an oral, blood-brain…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 57
- Next Page »